Capital Fund Management (CFM)’s MoonLake Immunotherapeutics MLTX Stock Holding History
Bought
Maintained
Sold
Other funds holding MLTX
Capital Fund Management (CFM)'s MLTX Position: Q3 2026 in Review
Capital Fund Management (CFM) reduced its MoonLake Immunotherapeutics (MLTX) stake by 10% in Q3 2026, selling an estimated $110K and leaving 58,644 shares worth $686K. The position accounts for ﹤0.01% of the portfolio, ranked #1645.
Capital Fund Management (CFM) first reported a position in MLTX in Q2 2024 and has held it in 4 quarters since. The position peaked at $1.29M in Q2 2024. 170 funds tracked by Wall St. Rank hold MLTX as of Q3 2026.
- Capital Fund Management (CFM) held 58,644 shares of MoonLake Immunotherapeutics worth $686K as of Q3 2026.
- Capital Fund Management (CFM) sold 6,750 MoonLake Immunotherapeutics shares in Q3 2026, an estimated $110K.
- MoonLake Immunotherapeutics made up ﹤0.01% of Capital Fund Management (CFM)'s portfolio in Q3 2026, its #1645 holding.
- Capital Fund Management (CFM) first reported a position in MoonLake Immunotherapeutics in Q2 2024 and has held it in 4 quarters since.
- Capital Fund Management (CFM)'s MoonLake Immunotherapeutics position peaked at $1.29M in Q2 2024.
- 170 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q3 2026.
Based on Capital Fund Management (CFM)'s 13F filing for Q3 2026, filed 13 Nov 2026.